EU approves Wyeth's improved hemophilia B drug

08/21/2007 | In-PharmaTechnologist.com

The European Union approved a new version of Wyeth's hemophilia B drug BeneFix. The improved product contains a lower diluent volume for all dosage strengths, comes in a prefilled syringe, has a bigger IU vial and features a needle-less reconstitution device. Wyeth hopes these changes will make the treatment easier for patients to prepare and use.

View Full Article in:

In-PharmaTechnologist.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY